Search
Now showing items 1-5 of 5
Effect of Remote Ischaemic Conditioning on the inflammatory cytokine cascade of COVID-19 (RIC in COVID-19): a Randomized Controlled Trial
(2022-11-29)
Purpose Patients hospitalized with COVID-19 may develop a hyperinflammatory, dysregulated cytokine “storm” that rapidly progresses to acute respiratory distress syndrome, multiple organ dysfunction, and even death. Remote ...
Antithrombotic in atrial fibrillation and coronary artery disease – Does less mean more?
(2022-06-15)
In the treatment of patients with chronic coronary syndrome, the use of antiplatelets in the form of aspirin is a class 1 indication in the prevention of future thrombotic events.1 Similarly, oral anticoagulation (OAC) has ...
Multicenter, Randomized, Active Comparator-Controlled, Double-Blind, Double-Dummy, Parallel Group, Dose-Finding Phase 2 Study Comparing the Safety of the Oral FXIa Inhibitor Asundexian with Apixaban in Patients with Atrial Fibrillation
(2022-04-09)
Background Direct-acting oral anticoagulant use for stroke prevention in atrial fibrillation is limited by bleeding concerns. Asundexian, a novel, oral small molecule activated coagulation factor XIa (FXIa) inhibitor, might ...
Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: An European and Asia-Pacific Expert Consensus Paper
(2022-03-22)
Whilst there is a clear clinical benefit of oral anticoagulation (OAC) in patients with atrial fibrillation (AF) and venous thromboembolism (VTE) in reducing the risks of thromboembolism, major bleeding events (especially ...